PD53: Bladder Cancer: Basic Research & Pathophysiology III

Podium Session Moderator(s)

• 

  Vinata Lokeshwar, PhD

  Professor and Chair Biochemistry and Molecular Biology; Professor of Urology
  Medical College of Georgia, Augusta University
• 

  Debasish Sundi, MD

  Assistant Professor
  The Ohio State University James Cancer Center
• 

  Joshua Meeks, MD, PHD

  Northwestern University

Presentations:

• 7:00 AM – 7:10 AM

  PD53-01: Molecular subtyping of N-methyl-N-nitrosourea (MNU) rat model of urothelial carcinoma reveals both luminal and basal signatures
  

  Podium Presenter: Kara Lombardo, BS
• 7:10 AM – 7:20 AM

  PD53-02: Cytotoxicity caused by cisplatin, venetoclax, and S63845 to urothelial carcinoma cells expanded in 3D organoids differs clearly from cytotoxicity to autologous 2D adherent cells
  

  Podium Presenter: Wilhelm K. Aicher
• 7:20 AM – 7:30 AM

  PD53-03: Schistosoma haematobium may promote bladder carcinogenesis through DNA binding of its homolog of the Interleukin-4-inducing principle from Schistosoma mansoni eggs
  

  Podium Presenter: Derick Osakunor, PhD – Childrens National Hospital
• 7:30 AM – 7:40 AM

  PD53-04: Biodegradable Device for Controlled Release of Cisplatin as Local Chemotherapy for Bladder Cancer
  

  Podium Presenter: Gilad E. Amiel, MD – RAMBAM Medical Center and Technion Medical School
• 7:40 AM – 7:50 AM

  PD53-05: Bladder cancer tumoroids and normal urothelial organoids as near-patient models to study bladder cancer tumorigenesis and predict treatment response
  

  Podium Presenter: Mathijs Pieter Scholtes, MD,MSc
• 7:50 AM – 8:00 AM

  PD53-06: Changes in mouse stool microbiome with exposure to bladder carcinogen N-butyl-N-(4-hydroxybuytl) nitrosamine (BBN): Longitudinal analysis
  

  Podium Presenter: Laura Bukavina, MD, MPH
• 8:00 AM – 8:10 AM

  PD53-07: Detection of Early-stage Bladder Cancer using Plasma Extracellular Vesicle Protein Biomarkers
  

  Podium Presenter: Jean M. Lewis, PHD,BS – Biological Dynamics
• 8:10 AM – 8:20 AM

  PD53-08: E-Cigarette Exposure in Mice Promotes Changes in DNA Methylation of the Bladder Urothelium
  

  Podium Presenter: Ibardo Alonso Zambrano, MD
• 8:20 AM – 8:30 AM

  PD53-09: Antibody drug conjugates and variant histology muscle-invasive bladder cancer: Are the targets present in primary and/or metastatic tumors?
  

  Podium Presenter: Fady Ghali, MD – University of Washington, Department of Urology
• 8:30 AM – 8:40 AM

  PD53-10: Identifying Bladder Urothelial Carcinomas Using Fluorescent Signal Intensity of pH Low Inserting Peptides
  

  Podium Presenter: Borivoj Golijanin, BS
• 8:40 AM – 8:50 AM

  PD53-11: Divergent Therapeutic Outcomes of STING Agonist ADU-S100 in Intratumoral and Intravesical Treatment Regimens in Syngeneic Murine MB49 and in the N-methyl-N-nitrosourea (MNU) Rat Model of Urothelial Carcinoma
  

  Podium Presenter: Alok Kumar Singh, PhD
• 8:50 AM – 9:00 AM

  PD53-12: Impact of tumour-infiltrating lymphocytes (TIL) in squamous cell carcinoma of the bladder.
  

  Podium Presenter: Severin Rodler